| Drug General Information |
| Drug ID |
D0YN1E
|
| Former ID |
DNC003635
|
| Drug Name |
3,6-Di-pyridin-4-yl-pyrazolo[1,5-a]pyrimidine
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C16H11N5
|
| Canonical SMILES |
C1=CN=CC=C1C2=CN3C(=C(C=N3)C4=CC=NC=C4)N=C2
|
| InChI |
1S/C16H11N5/c1-5-17-6-2-12(1)14-9-19-16-15(10-20-21(16)11-14)13-3-7-18-8-4-13/h1-11H
|
| InChIKey |
ZLISHOMLHVNDJG-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Vascular endothelial growth factor receptor 2 |
Target Info |
Inhibitor |
[1]
|
|---|
| mRNA of VEGFR1 |
Target Info |
Inhibitor |
[2]
|
| Vascular endothelial growth factor receptor 3 |
Target Info |
Inhibitor |
[2]
|
|
KEGG Pathway
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
Endocytosis
|
|
PI3K-Akt signaling pathway
|
|
VEGF signaling pathway
|
|
Focal adhesion
|
|
Proteoglycans in cancerhsa04014:Ras signaling pathway
|
|
HIF-1 signaling pathway
|
|
Transcriptional misregulation in cancer
|
|
Rheumatoid arthritishsa04014:Ras signaling pathway
|
|
NetPath Pathway
|
IL2 Signaling PathwayNetPath_9:TNFalpha Signaling Pathway
|
|
PANTHER Pathway
|
Angiogenesis
|
|
VEGF signaling pathway
|
|
Pathway Interaction Database
|
HIF-2-alpha transcription factor network
|
|
Beta3 integrin cell surface interactions
|
|
Signaling events mediated by TCPTP
|
|
SHP2 signaling
|
|
S1P1 pathway
|
|
VEGF and VEGFR signaling network
|
|
Integrins in angiogenesis
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
Notch-mediated HES/HEY networkglypican_1pathway:Glypican 1 network
|
|
S1P3 pathway
|
|
VEGFR1 specific signals
|
|
Signaling events mediated by VEGFR1 and VEGFR2vegf_vegfr_pathway:VEGF and VEGFR signaling network
|
|
VEGFR3 signaling in lymphatic endothelium
|
|
Reactome
|
Neurophilin interactions with VEGF and VEGFR
|
|
VEGF binds to VEGFR leading to receptor dimerization
|
|
Integrin cell surface interactions
|
|
EPHA-mediated growth cone collapse
|
|
VEGFA-VEGFR2 Pathway
|
|
VEGFR2 mediated cell proliferationR-HSA-194306:Neurophilin interactions with VEGF and VEGFR
|
|
VEGF binds to VEGFR leading to receptor dimerizationR-HSA-195399:VEGF binds to VEGFR leading to receptor dimerization
|
|
WikiPathways
|
Focal Adhesion
|
|
Nifedipine Activity
|
|
Cardiac Progenitor Differentiation
|
|
Signaling by VEGF
|
|
AngiogenesisWP306:Focal Adhesion
|
|
AngiogenesisWP1919:Signaling by VEGF
|
| References |
| REF 1 | Bioorg Med Chem Lett. 2002 Dec 16;12(24):3537-41.Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharmacokinetics. |
|---|
| REF 2 | Bioorg Med Chem Lett. 2002 Oct 7;12(19):2767-70.Synthesis and initial SAR studies of 3,6-disubstituted pyrazolo[1,5-a]pyrimidines: a new class of KDR kinase inhibitors. |
|---|
